Buy Articaine solution 40 ml/ml 1.7 ml cartridge 50 pcs
  • Buy Articaine solution 40 ml/ml 1.7 ml cartridge 50 pcs


Dosage form
Brand & Manufacturer
Package Size
There are not enough products in stock
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Articaine - a local anesthetic (thiophene derivative) for infiltration and conduction anesthesia in dental practice, has a pronounced local anesthetic effect. In tissues (in a weakly alkaline medium) it undergoes hydrolysis and releases a base that has lipophilic properties and easily penetrates through the membrane into the nerve fiber.

Articaine interacts with receptors, blocks sodium channels in the nerve fiber membrane, thus providing a local anesthetic effect.

The action of the drug begins quickly (the latent period is 1-3 minutes). Duration of action - 20 minutes. The rapid destruction of articaine to an inactive metabolite, articicic acid, is the cause of its very low toxicity, which allows repeated administration of the drug. In an acidic environment, the effect is reduced.


- infiltration and conduction anesthesia in dentistry.


1 ml
articaine hydrochloride 40 mg

Excipients: sodium chloride - 2.1 mg, water d / and up to 1 ml.

Articaine is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Articaine Binergia Russia solution
Articaine hydrochloride Binergia Russia ampoules

No customer reviews for the moment.

Write your review

Write your review


Dosage and Administration

Before the introduction of the drug is recommended to always conduct an aspiration test in order to avoid intravascular administration of the drug. The pressure on the piston during the administration of the drug should be adjusted depending on the tissue sensitivity. The introduction of the drug in the inflamed areas of the mucous is not recommended. Eating is allowed only after the restoration of sensitivity.

When uncomplicated removal of the teeth of the upper jaw in the non-inflammatory stage - to the vestibular depot 1.7 ml per tooth; if necessary, in addition - 1.0-1.7 ml. For anesthesia with palatal incisions and suturing to create a palatine depot - 0.1 ml. When removing the premolars of the lower jaw (5-5) in the uncomplicated stage, infiltration anesthesia gives the effect of conductive anesthesia. When preparing cavities and turning teeth for a crown, with the exception of the molars of the mandible - vestibular injection of 0.5-1.7 ml per tooth.

When performing one treatment procedure, the maximum dose for adults is 4 mg / kg body weight.

Adverse reactions

The drug is usually well tolerated by patients, however, the following side effects may develop:

From the central and peripheral nervous system (dose-dependent): stupor, sometimes progressing to loss of consciousness, respiratory disorders, sometimes progressing to stop breathing, muscle tremor, muscle twitching, sometimes progressing to generalized seizures.

Non-dose-dependent - dizziness, paresthesia, hypesthesia.

Sometimes, in case of violation of the correct injection technique with the introduction of a local anesthetic in dental practice, nerve damage is possible, in particular in such cases damage to the facial nerve may occur, which can lead to the development of facial paralysis.

On the part of the organ of vision: transient visual disturbances (lack of clarity of visual perception, blindness, double vision) arising during or after a short time after injection of a local anesthetic.

Since the cardiovascular system: lower blood pressure, heart failure and shock.

On the part of the digestive system: nausea, vomiting.

On the part of the immune system: allergic reactions. At the injection site, they can manifest as swelling or inflammation of the mucous membrane. Manifestations that are not associated with the site of administration can be skin hyperemia, conjunctivitis, rhinitis, and angioedema. Angioedema can be manifested by swelling of the upper and / or lower lips, cheeks, swelling of the vocal cords with a feeling of "lump in the throat" and difficulty swallowing, urticaria and difficulty breathing. Any of these manifestations can progress to anaphylactic shock.


- hypersensitivity to articaine or to other local anesthetic drugs of the amide group;

- megaloblastic B12-deficient anemia;

- angle-closure glaucoma;

- diseases of the central nervous system;

- chronic hypoxia;

- bronchial asthma;

- paroxysmal tachycardia;

- atrial tachyarrhythmia;

- severe violations of cardiac conduction (for example, atrioventricular block II-III degree, severe bradycardia);

- acute heart failure;

- arterial hypotension;

- voluminous maxillofacial operations, as well as for the duration of the intervention over 20 minutes;

- children's age up to 4 years (efficiency and safety were not studied).


Mothers with pre-eclampsia, bleeding in the last trimester of pregnancy.

Drug interactions

Local anesthetics enhance the action of drugs that depress the central nervous system.

When applied simultaneously:

- anticoagulants (ardeparin sodium, dalteparin sodium, danaparoid sodium, enoxaparin sodium, heparin, warfarin) increase the risk of hemorrhages and bleeding;

- monoamine oxidase (MAO) inhibitors (furazolidone, procarbazine, selegiline) increase the risk of arterial hypotension (it is necessary to cancel MAO inhibitors 10 days before the local anesthetic is injected);

- the effect of muscle relaxants is enhanced and lengthened;

- with narcotic analgesics an additive effect develops; increased respiratory depression;

- vasoconstrictor agents strengthen and lengthen the local anesthetic effect of articaine;

- cholinesterase inhibitors (anti-myasthenia agents, demekaria bromide, ecotiopate chloride), cyclophosphamide, thiotepa reduce articaine metabolism.

Articaine shows antagonism with anti-myasthenia agents on the effect on skeletal muscles, especially when used in high doses, which requires additional correction of myasthenia treatment.

When processing the injection site of a local anesthetic with disinfectant solutions containing heavy metals, the risk of developing a local reaction in the form of painful sensitivity, edema increases.

Metabolite procaine (para-aminobenzoic acid) is an antagonist of antimicrobial sulfanilamide agents.

Pregnancy and Lactation

The safety of using Articaine during pregnancy has not been established due to the lack of clinical data. Articaine penetrates the placental barrier.

The question of the use of the drug by a dentist can only be accepted if the potential benefit of its use justifies the potential risk to the fetus.

It has no effect on the fetus (with the exception of possible bradycardia) with any application technique and dose.

During lactation, there is no need to interrupt breastfeeding, as no clinically significant concentrations of Articaine are detected in breast milk.

Special instructions

Do not administer intravenously!

It is impossible to carry out an injection in the area of ​​inflammation.

To prevent infections (including hepatitis), it is necessary to ensure that with each sampling solution from the ampoule new sterile syringes and needles are always used. Open cartridges cannot be used again for other patients.

When removing the premolars of the lower jaw in the uncomplicated stage, infiltration anesthesia gives the effect of conductive anesthesia. Infiltration of mandibular anesthesia of the tongue, soft palate is ineffective - anesthesia with conduction anesthesia is required.

Patients are required to monitor the function of the cardiovascular system, respiratory system and central nervous system.

MAO inhibitors should be discontinued 10 days prior to local anesthetic administration.

Influence on ability to drive vehicles and occupations of potentially dangerous types of activity

During the period of treatment, care must be taken when driving and occupying other potentially dangerous activities that require high concentration of attention and speed of psychomotor reactions.


Symptoms: dizziness, motor agitation or stupor during administration, loss of consciousness, low blood pressure, bradycardia.

Treatment: when the first signs of overdose appear, it is urgent to stop the injection and give the patient a horizontal position, ensure free airway, control the number of heartbeats and blood pressure. In dyspnea, apnea - oxygen, endotracheal intubation, artificial lung ventilation (central analeptics are contraindicated); for convulsions - intravenously slowly short-acting barbiturates with simultaneous oxygen supply and hemodynamic control; for severe circulatory disorders and shock, intravenous infusion of electrolytes, glucocorticosteroids, plasma substitutes, albumin; during collapse and increasing bradycardia, epinephrine (adrenaline), 0.1 mg, is slowly administered intravenously, then intravenously, under the control of the number of heart contractions and blood pressure; with severe tachycardia and tachyarrhythmias - intravenous beta-blockers. Oxygen supply and blood circulation control are necessary in all cases.

  • Brand name: Articaine
  • Active ingredient: Articaine
  • Dosage form: The solution for injection is clear, colorless or with a yellowish tinge.
  • Manufacturer: Binergia
  • Country of Origin: Russia

Studies and clinical trials of Articaine (Click to expand)

  1. Comparison of articaine and lidocaine for infiltration anaesthesia in patients undergoing bone marrow aspiration and biopsy
  2. Articaine interaction with DSPC bilayer: a 13C and 31P solid-state NMR study
  3. Determination of articaine in human plasma by liquid chromatography–mass spectrometry and its application in a preliminary pharmacokinetic study
  4. Gas chromatographic and mass spectrometric analysis of articaine in urine
  5. Solid-phase extraction and high-performance liquid chromatographic determination of articaine and its metabolite articainic acid in human serum
  6. Effects of prilocaine and articaine on human leucocytes and reactive oxygen species in vitro
  7. Regional metabolism of articaine in 10 patients undergoing intravenous regional anaesthesia during day case surgery
  8. CHARMM-based parameterization of neutral articaine—A widely used local anesthetic
  9. State-Dependent Block of Na+Channels by Articaine Via the Local Anesthetic Receptor
  10. Comparative investigations on the efficacy of articaine 4% (epinephrine 1:200,000) and articaine 2% (epinephrine 1:200,000) in local infiltration anaesthesia in dentistry—a randomised double-blind study
  11. Comparison of onset and duration of action of soft tissue and pulpal anesthesia with three volumes of 4% articaine with 1:100,000 epinephrine in maxillary infiltration anesthesia
  12. Intramolecular hydrogen bonding in articaine can be related to superior bone tissue penetration: A molecular dynamics study
  13. High-performance liquid chromatography and preliminary pharmacokinetics of articaine and its 2-carboxy metabolite in human serum and urine
  14. Articaine buccal infiltration enhances the effectiveness of lidocaine inferior alveolar nerve block
  15. Buccal versus lingual articaine infiltration for mandibular tooth anaesthesia: a randomized controlled trial
  16. Comparison of ropivacaine and articaine with epinephrine for infiltration anaesthesia in dentistry – a randomized study
  17. Comparison of articaine 4% and lidocaine 2% in paediatric dental patients
  18. Chloroprocaine vs. articaine as spinal anaesthetics for day-case knee arthroscopy
  19. Articaine: An Effective Adjunctive Local Anesthetic for Painless Surgery at the Depth of the Muscular Fascia
  20. Letter: Is Articaine the Hypoallergenic Anesthetic?
  21. pDelayed-type hypersensitivity to subcutaneous lidocaine with tolerance to articaine: confirmation by in vivo and in vitro tests
  22. A Comparison Of Articaine And Lidocaine For Inferior Alveolar Nerve Blocks
  23. Unusual maxillary branch paraesthesia after an articaine inferior alveolar nerve block
  24. Articaine and lignocaine

8 other products in the same category: